S&P DJI Announces March 2019 Quarterly Rebalance
Filed with ASX · · 6 pages · English
Paradigm Biopharmaceuticals Ltd. on 6ix
Earlier from Paradigm Biopharmaceuticals
- Paradigms orphan Phase 2/3 clinical program progresses
- Paradigms supplementary Phase 2B data
- Presentation of Phase 2 clinical trial results
- PAR reports successful Phase 2 clinical trial
- Paradigm reports consistent OA pain reduction
Later from Paradigm Biopharmaceuticals
- Paradigm (PAR) Updated Investor Presentation
- Paradigms secondary endpoints successfully met
- Paradigm launches a$77.9M capital raise
- Paradigm updated corporate presentation
- Paradigm Confirms Capital Raise Commitments
Follow Paradigm Biopharmaceuticals into a list and get an email when it puts out news.
Follow Paradigm Biopharmaceuticals